

- This study assessed the efficacy and safety of nadifloxacin in the treatment of bacterial skin infections.
- Three comparative, open, multi-centric, and randomized clinical studies and one open-label, non-comparative, multi-centric, Post-marketing Surveillance (PMS) study were conducted across various centers in India.
- Sample size of the three clinical studies, Study 1, 2 and 3 were 272, 49, and 49, respectively, and that of the PMS was 329.
- Significant reduction in the mean scores of symptoms including erythema, crusting, exudation, swelling and pruritus was observed in nadifloxacin groups of all the studies ($p < 0.05$).
- Physician and patients rated the response to nadifloxacin as “excellent (complete remission of symptoms)”.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Wockhardt Ltd. (Mumbai, India). Medical writing assistance for this study was provided by Anupam Sharma (Knowledge Isotopes Pvt. Ltd., Mohali, India). For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Authors 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).